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Abstract: Bone is one of the most common sites for cancer metastasis. Bone tissue is composed by
different kinds of cells that coexist in a coordinated balance. Due to the complexity of bone, it is
impossible to capture the intricate interactions between cells under either physiological or pathological
conditions. Hence, a variety of in vivo and in vitro approaches have been developed. Various models
of tumor–bone diseases are routinely used to provide valuable information on the relationship between
metastatic cancer cells and the bone tissue. Ideally, when modeling the metastasis of human cancers
to bone, models would replicate the intra-tumor heterogeneity, as well as the genetic and phenotypic
changes that occur with human cancers; such models would be scalable and reproducible to allow
high-throughput investigation. Despite the continuous progress, there is still a lack of solid, amenable,
and affordable models that are able to fully recapitulate the biological processes happening in vivo,
permitting a correct interpretation of results. In the last decades, researchers have demonstrated that
three-dimensional (3D) methods could be an innovative approach that lies between bi-dimensional
(2D) models and animal models. Scientific evidence supports that the tumor microenvironment can
be better reproduced in a 3D system than a 2D cell culture, and the 3D systems can be scaled up for
drug screening in the same way as the 2D systems thanks to the current technologies developed.
However, 3D models cannot completely recapitulate the inter- and intra-tumor heterogeneity found
in patients. In contrast, ex vivo cultures of fragments of bone preserve key cell–cell and cell–matrix
interactions and allow the study of bone cells in their natural 3D environment. Moreover, ex vivo
bone organ cultures could be a better model to resemble the human pathogenic metastasis condition
and useful tools to predict in vivo response to therapies. The aim of our review is to provide an
overview of the current trends in bone metastasis modeling. By showing the existing in vitro and
ex vivo systems, we aspire to contribute to broaden the knowledge on bone metastasis models and
make these tools more appealing for further translational studies.
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1. Introduction
Cancer harbors variable heterogeneity and plasticity, which are both difficult features to reproduce
in experimental models but essential for maintaining intra- and inter-patients’ differences and for
accurately analyzing molecular mechanisms of the neoplastic transformation or for drug screening
purposes. While substantial progress has been made in developing anti-cancer treatment strategies
for primary tumors, such as breast and prostate cancer, the therapeutic interventions for metastatic
cancer still present challenges. These challenges are primarily due to the tumor heterogeneity between
and within individual patients, which results in significant differences in the tumor growth rate,
invasive ability, drug sensitivity, and prognosis among individual patients [1]. For these reasons,
there is a clear necessity to develop accurate cancer models to better investigate molecular mechanisms
that lead to cancer onset/progression and to find more effective treatment strategies.
The growth of metastasis at secondary sites is the major cause of mortality in cancer patients,
and it may be clinically evident even after years from the first diagnosis and therapy. Beyond lung
and liver, bone is the third tissue most frequently affected by metastasis [2,3], thus impacting patients’
quality of life. In fact, several human cancers, such as breast cancer (BC), prostate cancer (PC) and
lung cancer (LC), often metastasize to bone in their advanced stages [4]. These unfortunate events are
related to considerable morbidity, such as pathological fracture, spinal cord compression, bone pain,
and hypercalcemia, which, also due to the lack of curative treatment options, contribute to a worse
outcome [4].
Unfortunately, the process by which cancer cells from the primary tumor acquire an osteotropic
phenotype is still not well understood. Recently, Salamanna and colleagues reviewed different
studies that attempted to determine some of the factors that participate in both cellular and molecular
mechanisms of bone metastasis onset [5]. The ability to simplify the complexity and simultaneously
retain the major pathophysiological features of metastasis is necessary to identify the critical factors in
the acquisition of cancer metastatic potential. Recently, three-dimensional (3D) models and cancer
organoids have been increasingly used as a simplified and reliable in vitro model system to study bone
metastasis [5–7]. However, there are several limitations to the application of these models, such as
the lack of a purely native microenvironment and of a well-defined extracellular matrix (ECM) [8].
There is no better model to accurately represent the original tumor than an ex vivo model, consisting of
a specimen directly derived from patients and enriched with their own microenvironment components.
The main problem when producing this model, beside the availability of the biopsies, is the difficulty
of maintaining samples alive and proliferating while studying the characteristics of bone metastasis
and its response to therapy.
Our review aims to provide (1) a general background on the bone metastatic process;
(2) a comprehensive summary of the current 3D models and technologies showing their limitations and
advantages; and (3) an insightful overview of the current ex vivo bone metastasis models. Taking into
account the recent methods used in bone metastasis research, we want to underline the need for new
systems that are more innovative, easier to handle, and could better recapitulate the cancer biology
and bone metastasis. The primary goal of these models would be to increase the predictability of
preclinical data by improving the characterization of the models, implementing new methodologies
and integrating complementary models (e.g., ex vivo 2D and 3D assays) in drug development pipelines.
2. Metastasis Process and Bone Metastatic Microenvironment
The ability of cancer cells to leave a primary tumor, to disseminate through the body, and to seed
new secondary tumors is universally recognized to be the basis for metastasis formation. Various and
sometimes conflicting hypotheses have been proposed to explain different aspects of this process,
but no single concept unravels the mechanism of metastasis in its completeness.
A pioneer study conducted by Stephen Paget in 1889 hypothesized that metastasis is based
on the interplay between the so-called ‘seeds’ (namely the cancer cells) and the ‘soil’ (or the host
microenvironment) [9]. Paget’s theory was subsequently challenged by others studies, such as
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Ewing’s and Isaiah Fidler’s research [10,11]. Other important findings revealed that primary tumors
themselves are responsible for the formation of suitable microenvironmental conditions in distant
sites, being determinant for the sustainment of cancer cells survival and proliferation before the
establishment of the new colony [12–14]. Nowadays, this particular microenvironment is usually
referred to as ‘pre-metastatic niche’ [13,15]. The metastatic niche theory suggests that a properly
favorable microenvironment (pre-metastatic niche) supports tumor cells to engraft (metastatic niche)
and proliferate at secondary sites (micro- to macrometastatic transition). In particular, the pre-metastatic
niche results from the synergic interaction between the endogenous organ microenvironment and
specific factors secreted by primary tumors [15,16].
The bone niche is populated by different kind of cells including stem cells, progenitor cells,
mature immune cells, and supporting stromal cells [17–19]. To date, two primary niches have been
described, namely the osteoblastic niche and the perivascular one; they are characterized by two
diverse types of adult stem cells and their progeny: hematopoietic stem cells (HSCs) and mesenchymal
stem cells (MSCs) [19–21].
HSCs are multipotent progenitor cells that can be found in adult bone marrow, peripheral blood,
and umbilical cord blood. The hierarchical lineages of HSCs consist of myeloid cells, B lymphocytes,
and osteoclasts [22]. The MSCs are multipotent cells that are able to differentiate into the
mesenchymal lineage cells, which include osteoblasts, adipocytes, chondrocytes, fibroblasts, and other
stromal cells [19,20]. Both cells’ lineages are connected to each other in the bone niche and work
together to maintain bone homeostasis, sustaining in particular the osteogenesis, osteoclastogenesis,
and hematopoiesis processes.
Bone is a hierarchically organized connective tissue; it contains four types of cells—osteogenic cells,
osteoblasts, osteocytes, and osteoclasts—embedded in a matrix of collagen fibers and hydroxyapatite,
as an inorganic component. Osteogenic cells differentiate into osteoblasts [23]. When included into
the calcified matrix, osteoblasts undergo their terminal differentiation into osteocytes, changing their
structure and function. On the other hand, osteoclasts are large multinucleated cells derived from the
hematopoietic lineage (monocytes). Both osteoblasts and osteoclasts participate in the maintenance
of bone physiologic homeostasis; in fact, bone tissue is continuously remodeled in order to maintain
structure and calcium equilibrium, by osteoclast-mediated bone resorption and osteoblast-mediated
bone deposition [24].
In case of cancer progression, this equilibrium is usually altered, leading to osteoblastic, osteolytic,
or mixed metastatic lesions depending on the cancer origin and type [24]. In osteoblastic metastasis,
commonly found in PC patients, the metastatic bone is characterized by the deposition of new
tissue not preceded by bone resorption, resulting in excessive and disorganized bone formation [24].
Instead, osteolytic metastasis is mainly diagnosed in breast, lung, and renal cancers, and it is usually
present uncontrolled osteoclast activity [23]. In most of the cases, the two processes coexist; thus, is not
possible to classify bone metastasis as a single defined process, with the clinical prevalence of one over
the other [25].
The development of malignant bone metastasis is recognized as a dynamic multistep process,
in which a subpopulation of cancer cells from the primary tumor gain the capability to invade
surrounding tissues, intravasate, survive in the bloodstream, and extravasate, giving rise to the
metastatic colonization in a distant bone microenvironment [26]. Considering its complexity, a successful
approach to study the intrinsic biology of bone metastasis is to separate the various steps of the cascade
and to deeply characterize the bone metastatic microenvironment. Quiao and Tang extended the concept
of “fertile soil“, proposed by Paget, to include three distinct microenvironments: the primary tumor
microenvironment (PTM), the circulation microenvironment (CM), and the bone microenvironment
(BM), each one distinguished by several key points that will be further discussed [27].
In the context of the PTM, the formation of metastasis involves a subgroup of osteotropic
cancer cells with increased proliferative and migratory capacities [27]. Angiogenesis and epithelial to
mesenchymal transition (EMT) are critically important in this phase. The first responds to the increased
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metabolic demand of cancer cells supporting local invasion and distant dissemination [28]. In contrast,
the EMT consists of the cellular transformation from an epithelial phenotype with apical–basal
polarization to a mesenchymal one characterized by high motility features [29]. The activity of cancer
cells in the CM begins with intravasation and ends with extravasation. Tumor cells that trespass the
normal vascular endothelium using the newly formed microcapillaries, become circulating tumor
cells (CTCs), and invade the CM. Due to the overexpression of various surface receptors involved in
pro-survival pathways [30], these CTCs are able to evade anoikis and survive in the CM. Once CTCs
enter the BM, they are redefined as disseminated tumor cells (DTCs); here, DTCs can remain in a
dormant state for several years [31]. This condition, also known as “dormancy”, can revert in case
of stress circumstances, compromised immune system, and/or the activation of specific molecular
pathways, leading to the formation of macrometastases. When in the osseous tissue, CTCs influence the
pre-metastatic niche already developed in order to create a compatible niche to support the metastatic
growth (metastatic niche). This process has been largely studied particularly for BC and PC bone
metastasis and reproduced in the up-to-date available 3D model of bone metastasis formation [32]
(Figure 1).
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2.1. 3D Models
Three-dimensional architecture is fundamental for tissue and organ formation and intracellular
functions [33,34]. This is also true for neoplastic tissues, where cancerous cells spontaneously grow
and proliferate in a 3D structure within the host. Thus, an ideal 3D culture model should not only
resemble oncogenesis and in vivo tumor cell growth, but also imitate the interactions between cells
connected to the ECM. To date, several 3D strategies have been published, aiming to recapitulate as
best as possible the in vivo environ ent and als to bridge the gap between standard bi-dimensional
(2D) tissue culture and nimal mode s [35–37]. All these studies highlighted the mult ple differences
between 2D and 3D systems; thus, the interest in developing always more realistic models is constantly
increasing [33,38,39]. The use of 3D culture to recount the tumor bone microenvironment offers a
deeper understanding of bone metastasis and cancer biology by more faultless modeling of dynamic
cell–cell and cell–ECM interactions. However, there is still a lot of work to be done in 3D models
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research, specifically in finding more adequate biomaterials for models in terms of cellular growth,
reproducibility, scalability, and cost [40].
To date, several approaches have been explored. These methods can be divided into different
categories according to the technology used (Table 1; Figure 2). Generally, methods for 3D cell culture
can be classified as either scaffold-free or scaffold-based, with the scaffold being constituted by organic
or synthetic materials.Cancers 2020, 12, x 7 of 26 
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The models can also be divided on the basis of whether they are on static or dynamic cultures.
Static 3D cultures include the seeding of cells in a spheroid-like structure without the ECM and the
seeding of cells in matrices or scaffolds. Dynamic 3D cultures include either cell free scaffold or
scaffold-embedded cultured in bioreactors, or perfused in microfluidic devices (Table 1; Figure 2).
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Table 1. 3D Model Technologies Advantages and Limits. BC: breast cancer, BM: bone microenvironment, ECM: extracellular matrix, HA: hydroxyapatite, IL: interleukin,
OT: osteoblastic tissue, PC: prostate cancer, TME: tumor microenvironment.
3D Models Cancer Feature Studied Pros Cons Other References
Scaffold
free
Cancer cell invasion into the ECM [41];
Formation of tubule-like structure that mimics
vessel sprouting and angiogenesis [42];
Collective invasion and intravasation [43];
Collective invasion [44].
High Reproducibility;
Low cost;
Co-culture;
HTS approach.
No support or porosity;
Not optically transparent;
Poor control over
spheroids/organoids size;
No cell/ECM interactions.
[45–53]
Scaffold
based
Cell adhesion, proliferation, activation, and
differentiation to hold up metastatic cancer cell
growth and to resemble TME complexity [45];
Role of HA and IL8 in switching mammary
tumor cells toward a more invasive phenotype
[46]; Cancer cells and BM interplay is influenced
by spatial organization, osteogenic factors, and
stromal cell type [47];
Osteomimicry, the BM [48];
BM model of the BC metastatic niche [49];
PC cells in contact with osteoblast-like cells
embedded in 3D collagen gel system produced
morphological evidence of blastic reaction and of
local invasion [50];
Evaluation of metastasis development from
endometrial cancer, PC, and BC co-culture and
expression of biomarkers associated with PC
cells BM [51].
Co-cultures;
Large variety of materials;
Customizable;
Affordable cost;
High similarity to the
in vivo conditions;
Promotion of cellular attachment,
proliferation, and differentiation;
HTS approach sustainable.
Possible scaffold-to-scaffold
variation;
Not always optically transparent;
Difficult cells removal;
HTS options limited;
Gelling mechanisms;
Batch to batch variations;
Undefined constituents in
natural gels;
Poor mechanical properties.
[52–62]
Cultivation and
Biofabrication Systems Cancer Feature Studied Pros Cons Other References
Bioreactors
Reconstruction of a bone surrogate to study the
early stages of BC invasion to bone [63];
Co-culture of OT with metastatic BC cells [64];
Reproduction of the interaction between bone
stroma, PC cells, and human osteosarcoma cell
line [65].
High similarity to the in vivo
conditions;
High volume of cells production;
Customizable and controlled
culture parameters.
Space required for dynamic
cell culture;
High costs for dynamic cultures;
HTS options laborious.
[62,66–70]
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Table 1. Cont.
3D Models Cancer Feature Studied Pros Cons Other References
Microfluidic
Angiogenesis, intravasation [71];
Study of molecular pathways implicated in BC
cells extravasation, mediated by cell surface
receptor CXCR2 and bone-secreted chemokine
CXCL5 [72];
Microvascularized bone-mimicking
microenvironment, defined by active
differentiated bone cells, which generated
spontaneously molecular gradients affecting
both microvasculature and cancer cells [73];
3D multicellular spheroid composed by PC-3
metastatic PC cells, osteoblasts, and endothelial
cells [74].
Co-cultures (cell–cell, cell–tissue);
Control of cell shape and function;
Tune dynamic;
Fluid flow and
spatiotemporal gradient;
Customizable;
Commercial availability.
Required expertise;
High cost of microfabrication;
HTS options limited;
Microenvironment parameters
not measurable;
Cell growing media for co-culture
not well established.
[75–78]
Organ-on-a-chip
Tumor multiorgan metastasis and cancer
microenvironment interaction [73];
Development of a four organ-on-a-chip
system [79].
In vitro organ specific systems;
High gas permeability;
Optically transparent;
Commercial availability.
Required expertise;
High cost for the microfabrication;
HTS options limited
[80,81]
3D bioprinting
3D bioprinting fibers embedded in hydrogels to
recreate microvessels and study cancer-related
angiogenesis [82];
Proliferation and invasion ability [83];
Modeling tumor microenvironment [84];
Migration of osteotropic cells during bone
metastasis [85];
In vitro bone matrices to mimic the native BM
for the investigation of BC bone metastasis [86].
Automated robotic processes;
Spatially assembling multiple
types of cells;
Large variety of biomaterials and
printing technologies;
Bimolecular gradient production;
Printable, crosslinkable,
biocompatible and
bioactive bioinks.
High cost;
Required expertise. [56,75,87–89]
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2.2. 3D Models and Applications to Bone Cancer Metastasis Studies
2.2.1. 3D Scaffold-Free Systems-Cells Spheroids
The multicellular tumor spheroid (MCTS), developed by Sutherland and collaborators in the
1970s [90], has become a classic model system for cancer research and is the representative of the
scaffold-free systems subgroup. Spheroids are aggregates of cells that grow in suspension and resemble
a physiological neoplastic tissue organization with the outer zone containing proliferating cells,
the inner parts populated by few dividing cells with lack of nutrients and oxygen, and a central necrotic
area [91].
Different methods can be used to obtain spheroids from a vast range of cell lines [92,93].
Such spheroids are suitable for basic studies of physiology and metabolism, tumor biology, toxicology,
cellular organization, and the development of bio-artificial tissues. They represent a valuable tool
to mimic the tumor microenvironment while incorporating different types of cells, having a high
reproducibly rate and low related costs. However, not all cell lines form spheroids; some arrange in
irregular cell aggregates. Moreover, spheroids can be considered too simplistic and not appropriate
to simulate all the cell–cell and cell–ECM interactions that can affect the efficacy of anti-cancer
drugs [94]. Moving the model to a fully embedded system offers further opportunities to mimic a
tumor environment facilitating physiological cellular interactions, metabolism, growth, and metastatic
invasion. There are multiple approaches to embedding spheroids, the most common based on the use
of agarose, Matrigel, fibrin, synthetic polymers, and collagen [95]. The embedded spheroid model can
be used to investigate the mechanisms of cancer cell invasion into the ECM. For example, they were
used to monitor the invasion of glioma cells into collagen type I via imaging techniques [41]. There have
been some studies showing 3D spheroids in combination with 2D endothelial cells that are able to
form tubule-like structures that mimic vessel sprouting and angiogenesis [42]; however, there are no
particular examples of this with bone metastasis models.
2.2.2. Organoids
An organoid can be defined as a 3D-structured group of cells derived from primary tissue,
embryonic stem cells (ESCs), or pluripotent stem cells (PSCs), with self-renewal and self-organization
abilities, which are provided with similar functionality of the organ of origin. Organoids are
innovative 3D in vitro culture platform and can be important tools for modeling disease such as
cancer. They can recapitulate tumor heterogeneity and microenvironment, overcoming established
cell lines, and do not require the excessive time and costs of in vivo patient-derived tumor xenografts
(PDTXs). Furthermore, they can be stocked as “living biobanks”.
Since the discovery of colorectal cancer (CRC) organoids [96], 56 tumor-derived organoids have
been established (including prostate, bladder, ureter, kidney, colon/rectum, brain, pancreas, breast,
stomach, esophagus, soft tissue) [97,98]. Nevertheless, the majority of published structures referred as
organoids do not comprehend all cell types present in vivo, such as mesenchymal, stromal, immune,
and neural cells.
Organoids mimic some, but not all, of the structures and functions of real organs and cannot
recapitulate all the stages of cancer [99]. Firstly, they lack vasculature, which is essential to nutrient and
waste transport. Secondly, not all cell types found in vivo can generate organoids. Thirdly, some of them
replicate only the early stages of organ development. Taking into account all these limits underlines
that organoids are not completely suitable for modeling bone cancer metastasis or cancer metastasis in
general. However, patient-derived organoids (PDOs) may be a valuable tool to develop personalized
treatments. In fact, cultured PDOs deriving both from disease-site biopsies or healthy tissue provide
sufficient material for HTS application, or for in-depth phenotypic profiling allowing the identification
of crucial mutations, therefore guiding therapeutic choices. Furthermore, the possibility of growing
matched normal and diseased organoids from patients permit the screening also of combinations of
different drugs that specifically target the diseased tissue, thus reducing side effects.
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2.2.3. 3D Scaffold or Hydrogels Based Tumor Models
Scaffolds are 3D structures that can be made of diverse kind of materials with tunable
porosities, permeability, surface chemistry, and mechanical properties that are designed to mimic the
microenvironment of specific tissues. They can be composed of both biological or synthetic materials.
Biological scaffolds generally use naturally derived ECM (e.g., Matrigel and collagen) to help cell
adhesion and 3D structures formation. In respect of synthetic devices, natural ones offer a more similar
microenvironment to physiologic conditions in terms of growth factors, cytokines, hormones, and other
molecules [98]. Meanwhile, synthetic scaffolds have several clear advantages over other natural gels
for 3D cultures. Firstly, they generally provide higher reproducibility compared to biological ones.
Secondly, synthetic materials allow superior control over the scaffolds’ biochemical and mechanical
properties in 3D cell cultures. Thirdly, they possess high water content, permitting the transport
of oxygen, nutrients, waste, and soluble factors, all of which are important to cell functions [98].
Scaffolds can be made through a variety of techniques (e.g., 3D printing, particulate leaching,
electrospinning, casting), and by way of their tunable characteristics and material properties, they can
influence cell adhesion, proliferation, activation, and differentiation.
Recently, several 3D matrix-assisted assembly models of bone metastasis have been developed
on both naturally and synthetically derived matrices, particularly for prostate and breast cancer cell
metastasis studies. These models utilize scaffolds to support metastatic cancer cell growth and to
recapitulate tumor microenvironment complexity [45].
An example, performed on a fibroin-like scaffold, has been done by Talukdar and colleagues;
they demonstrated that the interaction of breast cancer cells (MDA-MB-231) with the BM
[human osteoblasts-like cells (MG63) and mesenchymal stem cells (MSCs)] varies with spatial
organization, the presence of osteogenic factors, and stromal cell type [47]. Another study by Cox et al.
showed that 3D collagen glycosaminoglycan scaffolds support the growth and mineralization of
4T1 breast triple negative carcinoma cells and that mammary cells are capable of osteomimicry.
These interactions contribute to the ability of cancer cells to preferentially colonize the BM [48].
Several studies have focused on creating a system modeling the BM of the BC metastatic niche.
For example, Marlow’s group developed a 3D-collagen matrix seeded either with human primary MSCs
or immortalized cell lines representing cell types found in human bone marrow [49]. Other authors
used a similar method with alternative biomaterials (e.g., silk-based biomaterials) [100].
One of the main problem to solve while designing a scaffold is the adequate supply of nutrients
in order to cultivate a viable tissue and maintain an appropriate level of oxygen. As a consequence
of the insufficient oxygenation, a typical condition of the inside of the tissue-engineered construct is
hypoxia. Moreover, this is also a common feature in solid tumors, including BC [101]. Low oxygen
tension drives the dissemination of metastasis, and it is associated to worse prognosis [102–104].
In particular, BC mainly metastasizes to bone, which is characterized by a hypoxic microenvironment,
despite the presence of a high vasculated system. Indeed, oxygen tension in the bone is lower than
the values reported for other tissues [from <1–6% (approximately 7–43 mm Hg) [105] versus 2% and
9% (14–65 mm Hg)] [106]. However, it is still difficult to monitor the regional oxygen gradients in the
bone, and more accurate models are needed to unravel this topic [104].
Liverani and colleagues presented a biomimetic 3D tumor model based on macroporous scaffolds,
which resembles the hierarchically organized structure of extracellular collagen [107,108]. There are
two different types of BC cell lines examined here by the authors: MCF-7 (estrogen-positive BC
cells, linked to good prognosis), and MDA-MB-231 (triple negative and aggressive BC cells) [109].
Their discovery shows in this experimental scenario that cells are able to build a hypoxic core niche,
with modified growth dynamics, and that more aggressive cancer cells are selected, similarly to what
happens during the in vivo disease progression [108].
To evaluate the metastatic development of endometrial, prostate, and breast cancer, Sourla and
colleagues [110] inoculated the KLE human endometrial cancer, MCF-7 and ZR-75 human breast cancer,
and PC-3 human prostate cancer cells into a 3D type I collagen gel system, which was previously
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loaded with MG-63 osteoblast-like cells. Their work demonstrated that in contact with a 3D collagen
gel system loaded with osteoblast-like cells, PC cells produce morphological evidence of blastic reaction
and of local invasion. Another remarkable example is the study performed by Thakuri et al. on a 3D
hybrid hydrogel system composed of collagen and alginate to examine the invasive capability of BC.
The authors demonstrated that human mammary fibroblast cells facilitated the migration of BC cells
out of spheroids and into the surrounding matrix [50].
To recreate microenviromental condition in vitro and increase understandings of PC metastasis,
Sieh et al. developed a co-culture system with PC3 and LNCaP prostate cancer cells on a medical-grade
polycaprolactone–tricalcium phosphate (mPCL-TCP) scaffold, finding increased expression levels of
several known biomarkers associated with PC cells’ bone metastasis [51]. Furthermore, the same
co-culture system can be an indirect 3D in vitro model to analyze paracrine interactions between PC
cells LNCaP and human osteoblasts (hOBs). In fact, including LNCaP cells into polyethylene glycol
(PEG) hydrogel with hOBs is possible to examine PC cells forming a multicellular mass similar to a
vascular tumor. Furthermore, the 3D structure allowed the diffusion of factors secreted by hOBs and
LNCaP cells that influenced each other (paracrine interplay) [51].
Focusing on bone mineral hydroxyapatite (HA), one of the main components of human bone ECM,
through a 3D composite scaffold made by polylactide-co-glycolide (PLG) and HA particles, it was
demonstrated that HA can directly regulate key steps of BC bone metastases [5,46]. Moreover, in the
same study authors showed that interleukin-8 (IL-8) is pivotal in this phase, providing mammary
epithelium cells with a more aggressive behavior [5,46]. Another 3D bone-mimicking system was set up
by Jin et al. using three human BC cell lines with different metastatic potential, namely MDA-MB-231,
MCF-7, and transfected MDA-MB-231. In this case, authors showed that decreasing HA particles’
size and concentration positively influenced BC cells adhesion and proliferation [111]. In parallel,
the co-culture of MSCs and MDA-MB-231 in the same 3D system showed that the presence of MSCs
cause an upregulation of metadherin expression, which is a recognized metastasis-associated gene in
BC [46].
Polymeric scaffolds use synthetic hydrogels or other biocompatible polymers to generate the
physical supports for 3D cultures. The most common hydrogels used for 3D culture include PEG,
poly (vinyl alcohol) (PVA), and poly (2-hydroxyethyl methacrylate) (PHEMA) [98,112]. Hydrogels are
employed for different purposes in the fields of 3D tumor models; for instance, they are widely
used for modeling angiogenesis and recreating metastatic BM due to the relative ease of supplying
and handling [112]. Synthetic hyaluronic acid hydrogels have been found to support the metastatic
potential of PC cells [113]. PLGA and poly(ε-caprolactone) (PCL) scaffolds are also used to study
microenvironment stimuli acting on tumor cells, which is similar to the inhibition of proliferation
and invasion with cytotoxic drugs [114]. Additionally, these materials can be used to examine
stem-like features and EMT process in comparison to a 2D system. For example, PC cells cultured
in a chitosan–hyaluronic acid matrix changed their features, developing invasion-like attributes,
proving that hyaluronic acid likely promotes the metastasis, EMT, and drug resistance of PC cells,
which is followed by the activation of downstream signaling involved in cancer malignancy [27,115].
Therefore, both natural and synthetic scaffolds are useful tools for bone metastasis studies; however, it is
important to evaluate the most suitable material, probably by combining the two together [27].
2.3. Cultivation and Biofabrication Systems
2.3.1. Bioreactors
The cultivation of cells in a bioreactor has two main objectives: cell expansion and improved
cells functionality. Bioreactors’ technology allows effective cell expansion by monitoring important
parameters: substrate consumption/metabolite production, cell growth, pH, temperature, and gas
supply. In dynamic bioreactor systems, the application of a fluid dynamics to the cellular
microenvironment prevents the accumulation of secreted biomolecules and shear stress that can
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induce different forms of differentiation. Spinner-flasks and stirred-tank bioreactors are dynamic
culture vessels employed to grow co-cultures of tumor cells [116], tumor cells in 3D as spheroids [117],
or scaffold-based cultures [118].
To date, there are several studies performed in bioreactors investigating the relationship between
bone and cancer cells. A bioreactor-based co-culture system has beneficial characteristics for the study
of the first stages of metastatic dissemination. For example, it can be used to study BC cells’ spread to
bone tissue, namely adhesion on endothelial cells and intravasation, the exit from the bloodstream,
and distant metastasis establishment.
In this scenario, Dhuriati et al. generated a bioengineered murine derived osteoblastic tissue (OT)
model with comparable features to physiologic bone tissue, emphasizing the ability of MDA-MB-231
BC cells to infiltrate and form colonies into the OT when co-cultured in a bioreactor [64]. Further studies
by Krishnan et al. were interested in making an estimation of the ability of a 3D bone surrogate made
of osteoblasts and osteoclasts co-cultured in a bioreactor, which was to be used as a predictive tool
of the early stages of BC metastasis to bone. With this purpose, they implemented the previously
mentioned system set up by Dhurjati et al. comparing different co-culture systems, using murine
osteoblasts MC3T3-E1 and human metastatic BC cells MDA-MB-231, or the metastasis-suppressed line
MDA-MB-231BRMS1, observing the degradation of OT by BC cells [63].
Another interesting application of a dynamic bioreactor has been set up by Paolillo and
colleagues [119], who used a multi-compartmental modular bioreactor in order to follow the adhesion
process that naturally occurs during metastasis when circulating cancer cells adhere and colonize
target tissues.
The authors proceeded by combining a millifluidic technique with a scaffold-based system:
a milli-scaled chamber (LiveFlow® system) for the fluidic culture of scaffolds and membranes under
low shear stress. In particular, human fibroblasts were grown on a 3D polystyrene scaffold, which was
placed at the bottom of the chamber and maintained in a dynamic culture condition. Then, stem-like
cancer cells derived from dissociated breast (MCF-7) or lung (A549) spheroids were added to the
system, and the inhibitory effect of integrin antagonists on cell adhesion was tested. Through this
system, the authors were able to set up a useful model to explore the initial steps of the metastasis
process that is also potentially useful for further drug screening research [119].
With the aim of reproducing the interaction between bone stroma, PC cells C4-2,
human osteosarcoma cell line MG63, and a wild-type immortalized human osteoblastic cell line
HS27A, Sung et al. co-cultured the different cell populations in a rotating wall vessel (RWN) bioreactor
system. The presence of C4-2 cells induced notable changes in both normal and osteosarcoma bone
stromal fibroblasts, both in terms of phenotypic and molecular features. These results highlight how in
3D conditions, it is possible to reproduce the interplay between the different population of cells that
modulate neoplastic growth and metastasis [65].
Typically, RWV bioreactors are employed to minimize physical forces; instead, another kind of
bioreactors is able to recreate the intrinsic forces present in a tumor microenvironment. The importance
of these interactions is underlined in direct co-culture studies where cancer cells and osteoblasts
are in contact. Instead, several authors chose to divide the bioreactor in separate compartments
through a cellulose membrane to observe the growth of OT alone or in co-culture with metastatic BC
cells [90,113,120]. Therefore, bioreactors are confirmed as a useful method for studying the interaction
between bone and metastatic cells.
2.3.2. Microfluidic
Microfabrication techniques and microfluidic technologies have been combined to create
microstructures that are able to manipulate small amounts (10−9 to 10−18 L) of fluids [78].
The microfabricated hollow channels can host different kind of cells and tissues, and they can
be manufactured to control cell shape and function. Moreover, these platforms allow controlling
dynamic fluid flows and spatiotemporal gradients in a 3D culture microenvironment [77].
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There are several applications for cancer studies [121]; in particular, some of the most important
steps of cancer metastasis can be simulated through these innovative systems. The continuous
perfusion of media by the microfluidic network [122] can mimic blood flow, resulting in a higher
ability of cells to extravasate [123,124]. Moreover, these devices can support 3D aggregates growth
and the co-culture of multiple cell lines in the same chip [94]. An indicative example of microfluidic
application is the possibility to recreate tumor–endothelial cells interaction, which is fundamental for
understanding the process of metastasis formation, including angiogenesis, intravasation, and cancer
cell colonization [71]. Furthermore, microfluidic systems have also been studied in detail to better
recapitulate the cancer cell–immune cell interactions, with the ultimate aim of increasing knowledge
on cancer immunotherapies [125]. In general, these kinds of systems are usually modeled to contain
a microvascular network used for organ-specific extravasation experiments and the co-culture of
multiple cell lines in the same chip.
A remarkable example of their application is the co-culture of tumor cells with endothelial cells
human umbilical vein endothelial cells (HUVEC) to study the intravasation process. Specifically, it has
been shown that the endothelial cells are able to form a lumen-like structure, and the tumor cells in
contact, under low fluidic conditions, can migrate toward the lumen [126].
Furthermore, microfluidic platforms can be modified in order to generate more complex and
dynamic models. For example, Bersini et al. implemented a microfluidic system with three media
channels and four gels to co-cultivate different types of cells. For this study, in particular, MSCs and
human umbilical vein endothelial cells (HUVECs) were used [72]. As a validation of their system,
the authors reported that molecular pathways critical for the extravasation of BC cells, mediated by
cell surface receptor CXCR2 and bone-secreted chemokine CXCL5, were activated [72].
Subsequently, Jeon et al. improved the previously described system by adding a third cell line,
namely the osteodifferentiated primary MSCs, and embedding the HUVECs in a fibrin gel in order
to resemble a BM matrix [73]. In this way, the authors were able to recreate a human bone-like
microenvironment in vitro. Additionally, the perfusion flow that was generated and maintained into
the microfluidic circuit allowed the recreation of a molecular gradient, influencing both cancer
and endothelial cells. Finally, the introduction of MDA-MB-231 BC cells allows observing the
extravasation process.
2.3.3. Organ-on-a Chip
The in vitro cultures combining organoids and microfluidics, broadly known as organ-on-a-chip
(OOC) models, have been extensively used to study various characteristics associated with tumor
progression such as growth, angiogenesis, migration, metastasis, and drug response. An OOC can be
defined as a device containing both cells and ECM, recapitulating tissues and organs in their original
structure [6,127]. This model has many advantages: more specifically, it allows a precise control
of the microenvironment, continuous flow perfusion culture, and it is suitable for high-throughput
applications. Additionally, it allows maintaining some of the main tumor microenvironment (TME)
features present in vivo such as multicellular interactions, ECM-based biochemical properties (by using
biomaterials to encapsulate the cells), biophysical signals and their gradients [128], hypoxia [129],
and others [76].
Notably, OOCs can be fabricated as platforms made of different mini-organs in the multiple micro
chambers linked via microfluidic channels to form a human microphysiological system. This provides
an extraordinary platform to study cancer multiorgan metastasis. Nevertheless, at present, most of
these systems are not set up for ex vivo specimens but still utilize primary cell lines or stem cell-derived
cells; therefore, they cannot totally mimic the histological and cellular features of native organs and
tumors [130].
Below, we report several examples of OOCs to study tumor multiorgan metastasis and
cancer–microenvironment interactions. To determine the mechanism of multiorgan metastasis from BC,
Jeon et al. presented a model where endothelial cells, MSCs, and osteoblast-differentiated cells (OBs)
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were cultured in 3D ECM to mimic bone marrow and muscle microenvironments with the microvascular
networks. Extravasation rates of metastatic BC cells were investigated on these microenvironments
with or without adenosine treatment. The authors reported that metastatic BC cells exhibited
distinct extravasation rates in relation to different microenvironments. Moreover, the inhibition
of the A3 adenosine receptor in BC cells resulted in an increased extravasation rate in the muscle
microenvironment [73].
In another study, a four OOC system was developed to model the metastasis of primary LC to
the downstream organs, including the brain, liver, and bone [79]. The results showed that metastasis
occurred in all four organs and displayed spatiotemporal heterogeneity over the different locations.
Nevertheless, all these examples are still made of cancer cell lines and could not represent the critical
features of the native tumor. In turn, the incorporation of metastatic tumor organoids with other OOCs
presents a better way for studying cancer multiorgan metastasis [131].
2.3.4. Bioprinting
3D bioprinting has arisen as an innovative method to develop functionalized living tissues and
organs. Recent works highlighted the potential of this platform to study bone disease, although a lack
of reports on cancer bone metastasis is still present [132].
Different approaches can be followed using an alternative combination of bio-inks, consisting of
cells and gel-like materials [89]. Bioprinting technology can be used to study angiogenesis and invasion
mechanisms, as demonstrated by Zhang et al. [133] and Mou et al. [83] for MCTSs and LC cells,
respectively. In addition, it has been shown that 3D bioprinting fibers embedded in hydrogels are
suitable to generate microvessels, which is useful to study cancer angiogenesis [82]. Another study,
utilizing BC cells cultured on a hydrogel substrate using a pre-custom bioprinting platform, proved the
feasibility of obtaining uniform spheroids, representing a controllable and high-throughput approach
for modeling the TME [84].
Another remarkable application of this technique is in the study of osteotropic cell migration
during bone metastasis. Through the use of 3D bioprinting, Huang et al. created a matrix with similar
features to the CM that was able to simulate the vascular pattern demonstrated in vitro [85]. The authors
showed that the caliper of the bioprinted microvessel was determinant in regulating the speed of cancer
cells. Another study, conducted on a bioprinted PEG scaffold, showed how invasion is also modulated
by the composition of the scaffold (in particular, its stiffness) and the morphology of the cells [134].
Combining 3D bioprinting and biomaterials, Zhu et al. fabricated a series of in vitro bone matrices
composed of PEG hydrogel and different concentration of nanocrystalline hydroxyapatite (nHA).
These scaffolds were designed to best recapitulate the native BM for the investigation of BC bone
metastasis. The researchers used a stereolithography-based 3D printer to fabricate a bone matrix with
finely tuned architecture; this optimized matrix was used to analyze the interaction between BC cells
MDA-MB-231 and human fetal osteoblasts (hFOB). BC cells co-cultured with hFOB cells on the matrix
directly affected the morphology, proliferation rate, and cytokine secretion of osteoblasts. IL-8 secretion
by osteoblasts was enhanced in the presence of MDA-MB-231 cells. Moreover, the authors reported
that the cellular organization in a 3D matrix was different compared to the monolayer culture; in fact,
BC cells co-cultured with osteoblasts within the 3D bone matrix formed multicellular spheroids [135].
These results demonstrated the reliability of this kind of 3D printed bone matrices to study bone
metastasis evolution.
2.4. Ex Vivo Models
Ex vivo models consist of freshly isolated biopsies both from healthy and/or diseased tissues
derived from patients. In these tumor sections, the heterogeneity of the original tissue and the
components of the surrounding microenvironment are preserved. These features make the ex vivo
cultures a potent tool for personalized therapies [136].
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To date, several approaches to culture ex vivo models have been proposed, including tissue slices
and explant cultures. Although these methods have been applied to different fields of research [137,138],
there are still technical problems and limitations to take into account (Figure 3) [139].Cancers 2020, 12, x 14 of 26 
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In general, the ex vivo culture setting allows maintaining the interactions within tumor cells and
the microenvironment. Unfortunately, the cells survive only for a few days [140]. In particular, it is
known that maintaining biopsies in culture preserving their viability and integrity is very complex.
One of the main challenges is to aintain an adequate level of oxygen within the tissue explant.
Fluctuations in its concentration result in modified cell features; on the other hand, oxygen variations
are typical of each tissue. In particular, oxygen levels are very low in bone tissue in comparison to other
sites. Moreover, commonly, in vitro culture conditions are maintained under a determinate amount of
oxygen (usually around 21%) [141], which is not representative of ost tissues and especially not for
bone. Indeed, this is a limit in a long-term monitoring of disease progression and in drug treatments.
Furthermore, patient-derived biopsies are often difficult to achieve, and the isolation and culture
methods need to be optimized for each tissue type [110]. Complex methods can lead to difficult
interpretation of the results, mainly due to the intrinsic heterogeneity of the samples. [142]. The main
advantages and limitations of the ex vivo models are reported in Figure 3.
2.4.1. Main Applic tion of Ex Vivo Expl ts: Viability for Long Term Culture, Analysis of Tissue
Architecture, and Response to Therapies
To date, few examples of primary tumor ex vivo models are reported in the literature. These models
are mainly used to investigate tissue architecture, viability for long-term culture, and response
to therapies.
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Usually, tissues are cultured in the form of 200 µm thick slices both patient- or patient-derived
xenograft (PDX)-derived and can be cultivated directly in culture medium or maintained in an
air–liquid interface [140,143]. In order to improve cell viability and tissue organization, tissue biopsies
can be cultured in a stirred system (approximately 150 rpm), which prevents oxygen zonation [144].
Moreover, tissue slices can be maintained on an air–liquid interface, nesting on top of a filter [144],
which acts as a physical support, reducing cell death and vacuolation [144,145].
To better study tumor tissue architecture, Tanos et al. skillfully demonstrated the ability to maintain
BC explants in culture up to 7 days in low-adhesion plates [146]. In this study, the authors managed to
keep apico–basal polarity and a microlayer of myoepithelial cells, which is typical of luminal epithelial
cells architecture. Moreover, thanks to the presence of a breast-like tissue organization, it has been
possible to preserve cell–cell communication and hormone responsiveness, which are mechanisms
that were not observed for BC cell lines nor for dissociated breast tissue. In conclusion, this work
reinforces the need to keep the original tissue architecture to address hormone action in the breast
and to preserve the original features of the tissue [146]. In order to further improve these kinds of
systems, perfusion-based bioreactors can be employed to extend the culture time of BC specimens up
to 15 days [147]. In this system, tissue integrity and cell viability were preserved, although cellularity
was decreased alongside time. In another study, colorectal and head and neck cancer explant cultures
were proposed as a co-clinical tool for the prediction of patient-specific drug response [148]. In this
model, explants were cultured for 72 h, conserving the original phenotype in a matrix-specific scaffold,
which was adapted for each tumor type. As a means to satisfy the needs of cytokines and growth
factors, tumor explants were cultured with the patient autologous serum. By combining the results
obtained with a machine learning algorithm, the authors obtained a prediction tool to evaluate tumor
response to a specific drug treatment.
2.4.2. Ex vivo Bone Metastasis Models and Applications
Ex vivo bone organ cultures were firstly developed in the 1990s with the purpose of modeling
the interactions between cancer cells and the bone niche [101,149]. These first models were used to
study bone growth, bone and cartilage matrix turnover, and the effects of cancer in bone [150–152].
More recently, this system has been employed to study mechanical loading, interactions between
different bone cell types, the molecular steps involved in bone resorption/formation, and cancer
progression [137]. In the past decades, a variety of creative assays have been developed to efficaciously
model an in situ bone environment. The use of primary bone tissue in such experiments offers a direct
way of sampling the skeletal milieu and where the process of metastasis can be studied [153]. Ex vivo
assays using fresh bone such as fetal rat long bones [154], mouse calvariae [149,155], or embryonic
metatarsals [156], have been used successfully to investigate cell-specific and heterogeneous populations,
to test potential bone anabolic agents, or to study vascular differentiation and growth [153].
Firstly, murine calvariae specimens dissected from postnatal mice have been employed to model
the tumor–bone niche. A fresh bone tissue was co-cultured in close proximity, but not in contact,
to cancer cells up to 7 days. This created a two-compartment static system that allows for paracrine
signaling between the fresh bone and tumor cells [157]. Bellido and colleagues further developed this
model, switching to a rotating culture system. This allowed a direct contact of freshly bisected postnatal
calvariae and tumor cells, in order to stimulate bone–tumor cell interactions [137]. A recent work
has extended this model to a more accurate system that is focused on the human bone–tumor niche,
by replacing rodents’ samples with human ones [158]. Uniform discs derived from fresh human bone
samples were co-inoculated with human PC cell lines, cultured over 7–14 days, and the distribution
of the different kind of cells was observed under study. This model shows that the adherence of PC
cells occurs both in trabecular bone regions, by forming independent tumor colonies similar to those
observed in human metastatic disease, and through direct interaction with the bone matrix, by invasion
of the cellular microenvironment and trabecular bone structure of the bone core slices [158].
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The incorporation of species-specific microenvironments attracting secondary tumor invasion is
another important step of the metastasis cascade under study. In an interesting work, Tulotta et al.
developed a novel humanized mouse model of ER+ and ER– BC PDX that was able to grow at the
primary site and spontaneously metastasize to a human bone environment [159]. In this model,
the authors mixed different approaches: 3D ex vivo PDX, 2D in vitro BC cells, and ex vivo bone
specimens. In particular, to obtain the human bone environment, bone discs from femoral heads
obtained from patients subjected to hip replacement surgery were implanted subcutaneously into
NOD/SCID mice. To study the metastatic process, 7 PDX tumors and 3 BC cell lines (MDA-MB-231-luc2,
T47D-luc2, or MCF7-Luc2 cells) were injected into the fourth mammary duct; the development of
metastases was followed by luciferase imaging and confirmed on histological sections. By analyzing
bone integrity, viability, and vascularization, it was demonstrated that after 4 weeks, bone implants
were alive, re-vascularized, and remodeled (as evidenced by the presence of osteoclasts, osteoblasts,
and calcein uptake). Moreover, by analyzing the expression profile of genes and protein during
different stages of metastasis, it was possible to demonstrate that BC cells underwent a series of
molecular changes through the metastatic process; this finding identifies molecules as useful metastatic
drivers that could be helpful in predicting future relapse in bone in BC patients. This highlights the
potential impact of this humanized model system in delivering translatable data from the laboratory
to the clinic [159]. Thanks to human bone xenotransplantation, the maintenance of an osteotropic
phenotype was demonstrated to be a key strength of this model. Furthermore, Lefley and colleagues
showed that cells not only metastasized to human bone implants but also formed metastases in mouse
bone [160]. In conclusion, the authors demonstrated that the implantation of femoral bone provided a
metabolically active, human-specific site for tumor cells to metastasize. Additionally, they proved that
this novel model could provide significant advancements in the modeling of BC bone metastasis [160].
2.4.3. A Comparison between In Vitro and Ex Vivo Models
As mentioned above, ex vivo bone metastasis cultures are a convenient alternative that bypasses
the limitations of in vitro models, including 2D primary cell culture and 3D culture. In vitro models
do not entirely reproduce the cellular diversity, and the complexity of interactions present in the
tumor niche and tumor heterogeneity is still difficult to be represented ex situ in a 3D model.
Nevertheless, 3D models can add more complexity and scalability when compared to 2D models.
Additionally, compared to 2D, the tumor environment can be better reproduced in a 3D model; this is
because in a 3D model, the tumor cells are isolated to grow heterotopically. Additionally, thanks to the
current technologies developed, 3D models can be scaled up for drug screening as effectively as the
2D systems.
Compared to in vitro models, cultured bone explants could better mimic the original features
observed in patients; in fact, they can maintain the natural position of osteocytes within the
extracellular mineralized matrix, thus retaining the in vivo 3D distribution and the innate proportion of
osteocytes compared with other cells (osteoblasts, osteoclasts, bone marrow cells, and endothelial cells).
Furthermore, organ cultures using human bone reproduce human conditions and are a useful tool to
test patients’ responses to therapeutic agents. Ex vivo bone organ cultures are an effective model to
simultaneously examine the anti-cancer efficacy and bone effects of therapies before moving to in vivo
experimentation. In comparison to animal models, ex vivo organ cultures faithfully reproduce results
seen in vivo and represent much less expensive screening models. On the other hand, as previously
described, working with patient-derived explants is not as easy as working with cell cultures, either in
terms of sample availability or in terms of experimental analysis and result interpretation [142].
It is important to underline the potential of both cell culture settings to be included as preclinical
testing models, alternatives, or adjuvant to animal models, to challenge the inter- and intra-tumor
heterogeneity of biological behavior and treatment response in human cancer. Despite the enormous
contribution of PDXs in improving the knowledge in cancer research, their use on a large scale for
drug screenings is not possible, from an animal welfare point of view as well as for financial reasons.
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3D models and ex vivo cultures derived from patients’ tissue retain genomic features and in vivo drug
response and can systematically and consistently be generated. This animal-free and cost-effective
drug development pipeline for HTS prior to in vivo testing using PDXs models is currently still under
investigation across cancer types and open for improvement.
3. Discussion
In the last decades, the study of cancer biology has progressed from 2D culture on glass plates to
complex 3D models of tissues, organs, and body systems. The numerous 3D models developed have
allowed for a deeper knowledge of cancer biology.
Several inherent obstacles impede the study of cancer metastasis in bone. They include the physical
difficulty of manipulating bone as a tissue, the complexity of obtaining ante-mortem samples of bone
metastases from human patients, the limited number of representative models that effectively mimic
human disease, and the inconvenience of identifying or monitoring cancer cells using in vivo or ex vivo
models. Furthermore, bone metastasis studies are also limited by the amount of time that the model
can be maintained in culture. Molecular oxygen is one of the most important variables to consider.
In fact, oxygen transport is limited in vitro either by culture medium or by tissue thickness, leading to
hypoxic areas, therefore restricting the viability of the explant. Several strategies can be followed to
overcome these problems, such as cultivating the samples into a bioreactor, using specific scaffolds
resembling the microvasculature or oxygen carriers [102]. Thus, it is difficult to achieve real-time
monitoring using in vivo or ex vivo models. In addition to this, a main disadvantage to take into
account is the scalability of the ex vivo models; considering the low availability of tissue samples from
metastatic patients, high-throughput analysis is almost impossible, while the personalized medicine
opportunity is relevant. For instance, with the ex vivo model of bone metastasis, it is possible to study
the specific response of patients using their own avatar of the metastasis in the lab before attempting
drug regimens or novel treatment.
A few in vitro models that can overcome the aforementioned shortcomings have been established
for bone metastasis studies, and the existing in vitro models are unable to fully replicate all the
pathological conditions. Simple 2D monolayer culture models failed to mimic the bone, as it is
a complex elastic tissue where different populations of living cells are embedded in a dynamic
environment. Most of the in vitro models currently used mainly include endothelial cells, not allowing
a complete study of the bone microenvironment. Commonly used in vivo models of PC and BC
metastasis include syngeneic rodent cancers and xenografts of human cancer in immunodeficient
mice. Unfortunately, these models rarely develop bone metastasis, and in the case of xenografts,
differential factors between species may inhibit the capacity of human cells to colonize murine bones.
Currently, the therapeutic approaches used to limit bone metastasis development aim to restore the
balance between osteoblast and osteoclast cells populations, such as bisphosphonates and denosumab
treatments. However, considering the presence of mixed metastatic lesions, the inhibition of the
osteolytic process could not be sufficient [161].
Several models that are able to mimic bone metastasis are under investigation. As demonstrated
by in vivo preclinical bone metastatic models of PC, it is possible to reproduce different aspects of
the disease using a variety of established cell lines. In particular, some are useful to study osteolytic
lesion, while others better resemble osteoblastic ones [162]. However, it is important to consider
that human PC bone metastasis is mainly osteoblastic, so cell lines that induce osteoclastic lesions
(for example, PC3 cells) cannot fully represent what happens in patients [162]. Additionally, cells after
series passages can lose their heterogeneity, and the use of immunodeficient animals is challenging and
cannot recapitulate host immune response. Therefore, 3D in vitro models are interesting alternatives
to replace animals in PC bone metastasis research, as argued previously [110,116]. Regarding BC bone
metastasis models, co-culture of cells in microfluidic platforms seems to be the elective method to
describe osteoblastic lesions [72,73], while none of these models include osteoclastic cell lines [161,163].
A bioreactor-based co-culture system has also beneficial characteristics for the study of the first stages
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of metastatic dissemination [64,164]. Combining different co-culture systems made of osteoblasts and
human metastatic BC cells, it is possible to observe the degradation of bioengineered osteoblastic tissue
by BC cells [63]. In addition to these, an alternative approach may be the co-culture of bone tissue
explants with cancer cells, preserving the natural microenvironment of bone. Furthermore, it is possible
to engineer a two-compartmental model to follow the paracrine signaling between bone and cancer
cells, and their osteolytic or osteoblastic differentiation [157,158,165]. Despite the aforementioned
advantages, this method is not broadly used, probably because of the scarce availability of fresh
bone tissue explants derived from patients, which are necessary either to maintain a bone-specific
microenvironment or species-specific osteotropism [5].
As a consequence, there is not a particular model system that could be more suitable to reproduce
osteoblastic rather than osteolytic lesions. In fact, to date, a modular approach is generally adopted in
order to recapitulate different steps of the metastatic cascade using translational models [162]. For the
reader’s convenience, a detailed description of these models of bone metastasis has been published by
Berish et al. [162]. The ability to make this intricate mechanism easier while at the same time retain
its major pathophysiological features is mandatory to identify the critical factors in the acquisition of
cancer metastatic potential.
In this review, we have discussed the evolution of 3D models, with a specific focus on bone
metastasis. We explored the main 3D models currently in use, going into their efficacy, limits,
and potential. Lastly, we analyzed the ex vivo models of bone metastasis and we focused on the aspects
that must be critically examined and improved, so that they can exert greater clinical impact in the future.
In our opinion, together with emerging 3D in vitro platforms, the use of ex vivo models might help
uncover variables inherent to tumor heterogeneity and metastasis, in order to corroborate hypotheses
formulated from studies employing less complex in vitro models. Especially, ex vivo models could be
used as avatar metastases for the prediction of drug response for personalized medicine.
In fact, the coordinated action of multiple cell types, growth factors, and ECM present in the
native neoplastic BM might influence cancer cells’ behavior differently to what usually happens in
standard in vitro models. In parallel, the analytical tools used for the interpretation of results need to
be improved in order to simplify the analysis process.
4. Conclusions
Metastasis is a common consequence of many types of tumors. A major challenge in the clinical
translation of potential anticancer drugs and treatments is the discrepancy in the in vitro to the
in vivo efficacy of candidates. For this reason, there is an urgent need for stable and precise models
recapitulating cancer onset and metastasis. To this end, 3D preclinical models have emerged as
promising technologies attracting increasing multi-faceted recognition for its utilization in cancer
biology and metastasis studies by allowing for the recapitulation of the in vivo TME at high reliability
outside the human body. However, ex vivo patient-derived models are the only system that is able to
fully resemble inter- and intra-patient heterogeneity. The motivation here is to improve our capacity in
bone metastasis modeling over existing strategies, in attempts to facilitate drug development as well
as personalized therapeutic screening, especially for the latter, where the use of ex vivo models may be
conveniently combined with patient-derived cells, 3D dynamic systems, and materials. Indeed, ex vivo
models are anticipated to bridge the gap between conventional 2D cell cultures and animals, and they
can possibly even replace animal models (e.g., PDXs) in the case of personalized medicine.
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